These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12908013)

  • 1. Efficacy of interferon retreatment on interferon-resistant patients with chronic hepatitis C.
    Egusa K; Kondo J
    Acta Med Okayama; 2003 Jun; 57(3):151-8. PubMed ID: 12908013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased response rate to interferon therapy after a second course in hepatitis C patients who show relapse after the initial course.
    Arase Y; Ikeda K; Chayama K; Murashima N; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Kumada H
    J Gastroenterol; 2000; 35(8):607-12. PubMed ID: 10955599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
    Carr C; Hollinger FB; Yoffe B; Wakil A; Phillips J; Bzowej N; Leung J; Mirro K; Poordad F; Moore DH; Gish RG
    Liver Int; 2007 Oct; 27(8):1111-8. PubMed ID: 17845540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study.
    Serfaty L; Thabut D; Zoulim F; Andreani T; Chazouillères O; Carbonell N; Loria A; Poupon R
    Hepatology; 2001 Sep; 34(3):573-7. PubMed ID: 11526544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
    Taliani G; Gemignani G; Ferrari C; Aceti A; Bartolozzi D; Blanc PL; Capanni M; Esperti F; Forte P; Guadagnino V; Mari T; Marino N; Milani S; Pasquazzi C; Rosina F; Tacconi D; Toti M; Zignego AL; Messerini L; Stroffolini T;
    Gastroenterology; 2006 Apr; 130(4):1098-106. PubMed ID: 16618404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].
    Liu JP; Kang Y; Shang J; Ding GQ; Xiao EH; Wei JF; Cao Q
    Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):656-8. PubMed ID: 24160338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP).
    Cammà C; Giunta M; Chemello L; Alberti A; Toyoda H; Trepo C; Marcellin P; Zahm F; Schalm S; Craxì A
    Hepatology; 1999 Sep; 30(3):801-7. PubMed ID: 10462389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C.
    Mangia A; Minerva N; Annese M; Leandro G; Villani MR; Santoro R; Carretta V; Bacca D; Giangaspero A; Bisceglia M; Ventrella F; Dell'Erba G; Andriulli A
    Hepatology; 2001 Apr; 33(4):989-93. PubMed ID: 11283865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of efficacy of interferon treatment of chronic hepatitis C and occurrence of HCC after interferon treatment by a new classification.
    Kim KI; Sasase N; Taniguchi M; Mita K; Kim SR; Tanaka K; Hayashi Y
    Intervirology; 2005; 48(1):52-8. PubMed ID: 15785090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon retreatment in chronic hepatitis C: which patients to choose, and what schedule to use.
    Picciotto A; Campo N; Brizzolara R; Sinelli N; Torre F; Cipriani AG; Ponassi I; Varagona G; Grasso A; De Leo P; De Conca V; Mesiti S; Marenco G; Menardo G; Dodero M; Celle G
    Eur J Gastroenterol Hepatol; 1999 Jun; 11(6):649-53. PubMed ID: 10418937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of pretreatment viral load and monitoring of serum hepatitis C virus RNA in predicting responses to interferon-alpha2a treatment of chronic hepatitis C. Hanshin Chronic Hepatitis C Study Group.
    Wada M; Kang KB; Nishigami T; Shimoyama T
    J Interferon Cytokine Res; 1997 Nov; 17(11):707-12. PubMed ID: 9402109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.
    Cotonat T; Quiroga JA; López-Alcorocho JM; Clouet R; Pardo M; Manzarbeitia F; Carreño V
    Hepatology; 2000 Feb; 31(2):502-6. PubMed ID: 10655277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of pegylated interferon α-2b and ribavirin in chronic hepatitis C virus (genotypes 1 and 4) infection.
    Wiśniewska-Ligier M; Pawłowska M; Pilarczyk M; Halota W; Woźniakowska-Gęsicka T
    J Pediatr Gastroenterol Nutr; 2013 Dec; 57(6):694-9. PubMed ID: 23942001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.